Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Academic Article uri icon

Overview

abstract

  • Fourteen patients with advanced renal cell carcinoma were treated on a phase II trial with liposomal encapsulated doxorubicin (Lipodox, LED). None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity and no cardiac toxicity was evident. Seventy-nine percent (11 of 14) of patients experienced grade III or IV neutropenia. In summary, LED did not show antitumor activity in the treatment of advanced renal cell carcinoma.

publication date

  • January 1, 1994

Research

keywords

  • Carcinoma, Renal Cell
  • Doxorubicin
  • Kidney Neoplasms

Identity

Scopus Document Identifier

  • 0028662080

PubMed ID

  • 7775134

Additional Document Info

volume

  • 12

issue

  • 4